<p>Tycho Speaker of Transderm Inc. in the United States, along with Juvaris Biotherapeutics, will test the efficacy of a dry microneedle skin patch loaded with malaria antigens and a novel adjuvant for its ability to stimulate a robust immune response. If successful, this painless, low-cost, no-refrigeration vaccine delivery system could increase vaccine access to at-risk populations.</p>


Tycho Speaker of Transderm Inc. in the United States, along with Juvaris Biotherapeutics, will test the efficacy of a dry microneedle skin patch loaded with malaria antigens and a novel adjuvant for its ability to stimulate a robust immune response. If successful, this painless, low-cost, no-refrigeration vaccine delivery system could increase vaccine access to at-risk populations.